Core Insights - Bionano Genomics reported a decrease in total revenue for Q4 2025 and full year 2025, with total revenue of $8.0 million for Q4, down 3% from $8.2 million in Q4 2024, and $28.5 million for the full year, down 7% from $30.8 million in 2024 [4][21]. Financial Performance - Q4 2025 saw consumables and software revenues decrease by 1%, while instrument revenue slightly declined from $2.8 million in Q4 2024 to $2.7 million in Q4 2025 [4]. - The company sold 7,554 nanochannel array flowcells in Q4 2025, a 6% decrease from 8,058 flowcells sold in Q4 2024 [4]. - The installed base of OGM systems increased by 4% to 387 at the end of Q4 2025, up from 371 at the end of Q4 2024 [4]. - Gross margin improved to 43% in Q4 2025 from 42% in Q4 2024, with non-GAAP gross margin also at 43% [4]. - Operating expenses were reduced by 22% to $11.9 million in Q4 2025, and non-GAAP operating expenses decreased by 9% to $9.7 million [4]. Business Highlights - The company noted a 47% increase in the Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies, effective in 2026 [2][10]. - Bionano Symposium 2026 showcased advances in OGM, with nearly 40 presentations highlighting its applications in various fields, including hematologic malignancies and oncology research [10]. - The company reported 136 peer-reviewed publications in Q4 2025, indicating growing acceptance of OGM as a cytogenetic standard [10]. - Bionano initiated revenue guidance for Q1 2026 in the range of $6.5 to $6.7 million and for the full year 2026 in the range of $30 to $33 million [10]. Cash Position - As of December 31, 2025, Bionano ended the year with cash, cash equivalents, and available-for-sale securities totaling $29.6 million [4].

Core Insights - Bionano Genomics announced a study demonstrating that optical genome mapping (OGM) can effectively address limitations of targeted RNA-sequencing (RNA-seq) in detecting gene rearrangements in acute leukemias [1][4][5] Summary of Findings - The study published by The University of Texas MD Anderson Cancer Center indicates that OGM can identify a higher proportion of clinically significant structural variants (SVs) compared to a 108-gene targeted RNA-seq panel [4][5] - A total of 234 gene rearrangements or fusions were detected by OGM and/or RNA-seq across 206 subjects, representing 43.6% of a cohort of 467 acute leukemia research subjects [8] - OGM uniquely identified 37 events (15.8%), while RNA-seq uniquely identified 22 events (9.4%), highlighting the complementary nature of both technologies [8] - RNA-seq detected only 20.6% of the enhancer-hijacking events identified by OGM, emphasizing the importance of OGM in detecting critical gene rearrangements [8] Company Overview - Bionano Genomics provides genome analysis solutions aimed at transforming the understanding of the genome through OGM, diagnostic services, and software [6] - The company offers OGM solutions applicable across various research domains, along with a platform-agnostic genome analysis software and nucleic acid extraction solutions [6]

Core Insights - Bionano Genomics has published a book series focusing on chromoanagenesis, emphasizing the advantages of optical genome mapping (OGM) in this area of research [1][4] - Chromoanagenesis is linked to complex karyotypes and poor prognosis in cancers, making its detection crucial for understanding disease biology [2][4] - OGM offers high-resolution genome-wide views of structural variants, facilitating the identification of genomic variations associated with chromoanagenesis [2][4] Company Overview - Bionano Genomics specializes in genome analysis solutions, aiming to transform genomic insights through OGM technology and related services [5] - The company provides OGM solutions applicable in various research fields, including basic, translational, and clinical research [5] - Bionano also offers diagnostic testing services through its subsidiary, Lineagen, Inc., which utilizes OGM technology [5] Research Developments - The initial study utilizing OGM for chromoanagenesis was published in January 2025, focusing on acute myelogenous leukemia (AML) [3] - The book series includes studies expanding OGM applications to other cancers like multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) [3] - New methodologies, such as dam-assisted fluorescent tagging of chromatin accessibility, are being developed for detailed analysis of chromatin structures [3]

Core Insights - Bionano Laboratories announced the establishment of a new Category I CPT code for optical genome mapping (OGM) in cytogenomic genome-wide analysis, effective January 1, 2026, which is crucial for reimbursement from third-party payers [1][2][3] Group 1: CPT Code Significance - The new CPT code is the second issued for OGM, following code 81195 established in 2024 for hematological malignancies, indicating that OGM has met rigorous Category I standards [2] - The approval of this CPT code is expected to enhance the awareness and utility of OGM in both oncology and clinical genetic testing communities [3] Group 2: Bionano Laboratories' Offerings - Bionano Laboratories provides CLIA-certified laboratory developed tests (LDTs) utilizing OGM technology to detect structural and copy number variations related to genetic disorders [1][4] - The OGM-Dx Postnatal and Prenatal Whole Genome SV tests are designed to detect all classes of structural variants traditionally tested by multiple methods, showcasing the advantages of OGM over legacy methods [3] Group 3: Company Overview - Bionano Genomics aims to transform genome analysis through OGM solutions, diagnostic services, and software, catering to applications across basic, translational, and clinical research [5]